Publications

Pubblications

and downloads

Predictors of Viral Rebound in Children Living with HIV Initiating Second-Line Antiretroviral Therapy in the ODYSSEY and CHAPAS-4 Trials

Authors: Amuge P, Wyncoll J, Mujuru HA, Kekitiinwa AR, Lugemwa A, Kityo CM, Chabala C, Nyathi M, Nduna B, Musoke P, Srirompotong U, Violari A, Archary M, Cotton M, Mulenga V, Bwakura-Dangarembizi M, Elyanu PJ, Yawe I, Kaudha E, Musoro G, Ankunda R, Ndebele W, Mwamabazi M, Doerholt K, Giaquinto C, Rojo P, Gibb D, Bamford A, Musiime V, Turkova A, Ford D; on behalf of the ODYSSEY trial and CHAPAS-4 trial teams.

Presented at: International Workshop on Pediatrics and HIV

Read

T-cell subsets, T-cell receptor repertoire and HIV-1 virological reservoir in children initiating first-line dolutegravir versus standard-of-care ART: results from the ODYSSEY trial

Authors: Gärtner K, Wyncoll J, Hammer ASB, Rattenborg MN, Adams S, Byott M, Alber D, Botha JC, Kekitiinwa AR, Kityo C, Bamford A, Bwakura-Dangarembizi M, Violari A, Ounchanum P, Lugemwa A, Rojo P, Giaquinto C, Gibb D, Ford D, Turkova A, Sandgaard KS, Nastouli E; ODYSSEY trial team.

Published in: International Workshop on Pediatrics and HIV

Read

Dolutegravir as First- or Second-line Treatment for Children With HIV: 240-Week Follow-up of the ODYSSEY Randomized Trial

Authors: Mujuru HA, White E, Kekitiinwa AR, Lugemwa A, Kityo C, Violari A, Ahimbisibwe GM, Variava E, Archary M, Cotton M, Ounchanum P, Puthanakit T, Kanjanavanit S, Ngampiyaskul C, Kobbe R, Bandi S, Epaiza C, Bwakura-Dangarembizi M, Bbuye D, Kasozi M, Kaudha E, Cressey TR, Giaquinto C, Jafta L, Bamford A, Rojo P, Gibb DM, Turkova A, Ford D, on behalf of the ODYSSEY Trial Team

Published in: Open Forum Infectious Diseases

Read

Weight gain, body composition, and metabolic parameters of dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: an ancillary analysis of the ODYSSEY trial

Authors: Chan MK, Crichton S, Mujuru HA, Kekitiinwa AR, Lugemwa A, Kityo CM, Ahimbisibwe GM, Variava E, Violari A, Cotton M, Archary M, Cressey TR, Puthanakit T, Bandi S, Bwakura-Dangarembizi M, Bbuye D, Atwine L, Kaudha E, White E, Giaquinto C, Rojo P, Gibb DM, Turkova A, Ford D, and the ODYSSEY Trial Team.

Published in: The Lancet Child and Adolescent Health

Read

Weight gain, body composition, and metabolic parameters of dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: an ancillary analysis of the ODYSSEY trial

Authors: Turkova A, White E, Violari A, Mujuru HA, Kekitiinwa AR, Lugemwa A, Kaudha E, Na-Rajsima S, Ahimbisibwe GM, Variavae E, Archary M, Akhalwaya Y, Puthanakit T, Bwakura-Dangarembizi M, Bbuye D, Kasozi M, Liberty A, Königs C, Welch SB, Riault Y, Bamford A, Cressey TR, Musoke P, Kityo C, Ferrand R, Giaquinto C, Rojo P, Gibb DM, Ford D; ODYSSEY trial team.

Published in: The Lancet Child & Adolescent Health

 

Read

Pregnancies among adolescents and young women on dolutegravir vs standard-of-care in the ODYSSEY trial and effects of the dolutegravir neural tube defect safety alert

Authors: Ahimbisibwe G, Wyncoll J, Mngqibisa R, White E, Bwakura-Dangarembizi M, Kekitiinwa AR, Lugemwa A, Kityo CM, Variava E, Liberty A, Kataike H, Ngampiyaskul C, Cotton MF, Riault Y, Archary M, Smit T, Puthanakit T, Shakeshaft C, Nhema R, Bbuye D, Atwine L, Kaudha E, Giaquinto C, Rojo P, Bamford A, Gibb DM, Turkova A, Ford D, Musoke P, and the ODYSSEY Trial Team

Presented at: International workshop on pediatrics and HIV 2025

 

Read